1 January 2026 in Journal of Interventional Cardiology
Background: Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS. Methods: A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups. Results: The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure. Conclusions: In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.
3 June 2026 in Journal of Cardiovascular Translational Research